Original Source(s)
Related Content
FDA revises monitoring for SCLC therapy
Initial monitoring decreases from 22 to 24 hours to 6 to 8 hours from the start of the first 2 infusions.
September 15, 2026
-
2 min
FDA approves combo for ESR1-mutated breast cancer
In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.
September 21, 2026
-
2 min
FDA raises TMB threshold for pembrolizumab
Traditional approval narrows eligibility for previously treated solid tumors after efficacy was not confirmed at lower biomarker levels.
by Mouj Hijazi
October 23, 2026
-
3 min
